Pazopanib versus sunitinib in metastatic renal-cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Indoles
  • Kidney Neoplasms
  • Pyrimidines
  • Pyrroles
  • Sulfonamides

abstract

  • Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazopanib. (Funded by GlaxoSmithKline Pharmaceuticals; COMPARZ ClinicalTrials.gov number, NCT00720941.).

publication date

  • August 28, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1303989

PubMed ID

  • 23964934

Additional Document Info

start page

  • 722

end page

  • 31

volume

  • 369

number

  • 8